Ligand Pharmaceuticals LGND Derivative, Gain (Loss) on Derivative, Net
Derivative, Gain (Loss) on Derivative, Net at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DerivativeGainLossOnDerivativeNet.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's derivative, gain (loss) on derivative, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's derivative, gain (loss) on derivative, net?
- Ligand Pharmaceuticals (LGND) reported derivative, gain (loss) on derivative, net of $0 in Q1 2026.
- How has Ligand Pharmaceuticals's derivative, gain (loss) on derivative, net changed year-over-year?
- Ligand Pharmaceuticals's derivative, gain (loss) on derivative, net decreased by 100.0% year-over-year, from $443K to $0.
- What does derivative, gain (loss) on derivative, net mean?
- This metric tracks the net impact of changes in the fair value of derivative financial instruments, such as options, warrants, or hedging contracts. These gains or losses are typically non-operating in nature and reflect market volatility or the effectiveness of risk management strategies. It is essential for understanding how financial market fluctuations impact the company's bottom line outside of core business operations.